CDER’s Galson Cites Application Flaws, Not Politics, In Plan B Decision
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs submitted a marketing plan for behind-the-counter sale of Plan B (levonorgestrel .75 mg), but FDA was "unable" to review the package
You may also be interested in...
Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock
An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January
Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock
An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January
Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock
An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January